

R H I N O M E D

MAKE EVERY BREATH COUNT

SLEEP APNEA CLINICAL TRIAL UPDATE

May 25, 2016. Melbourne, Australia.

Rhinomed refers to its announcements on 15 June 2015 and 29 March 2016 and advises that the recruitment of its Phase I pilot clinical trial of its INPEAP (Intra Nasal Positive Expiratory Airway Pressure) technology for the treatment of Obstructive Sleep Apnea (OSA) has been completed and the lead Investigators are currently collating the data for analysis.

The Company will update the market on progress in due course.

Media Enquiries

Michael Johnson, CEO & Managing Director

+61 (03) 8416 0900

mjohnson@rhinomed.global

Follow us on

Twitter @rhinomedceo and @mutesnoring

About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep). For more information, go to www.rhinomed.global.